Xtl Biopharmaceuticals (XTLB) Non-Current Assets (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Non-Current Assets of $7.2 million for Q4 2024, up 1797.37% year-on-year from $380000.0 in Q1 2024, and up 1797.37% on a QoQ basis from $380000.0 in Q4 2023.
Xtl Biopharmaceuticals (XTLB) Non-Current Assets (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Non-Current Assets for 13 consecutive years, with $7.2 million the latest figure, recorded in Q4 2024.
- Quarterly Non-Current Assets rose 1797.37% year-over-year to $7.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $8.0 million (down 4.56% YoY) and the FY2024 annual result came in at $7.2 million, up 1797.37% from the prior year.
- Non-Current Assets improved to $7.2 million in Q4 2024 per XTLB's latest filing, from $380000.0 in the prior quarter.
- Over the last five years, Non-Current Assets for XTLB reached as high as $7.2 million in Q4 2024 and fell as low as $380000.0 in Q4 2022.
- A 5-year average of $1.4 million and a median of $381000.0 in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slipped 0.26% — and 2024, when it jumped 1797.37%.
- Year by year, Non-Current Assets stood at $382000.0 in 2020, then dropped by 0.26% to $381000.0 in 2021, then retreated by 0.26% to $380000.0 in 2022, then changed by 0.0% to $380000.0 in 2023, then soared by 1797.37% to $7.2 million in 2024.
- According to Business Quant data, Non-Current Assets over the past three periods registered $7.2 million, $380000.0, and $380000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | 285.82 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.21 Mn |
| Dec 31, 2023 | 380,000.00 |
| Dec 31, 2022 | 380,000.00 |
| Jun 30, 2022 | 381,000.00 |
| Dec 31, 2021 | 381,000.00 |
| Jun 30, 2021 | 382,000.00 |
| Dec 31, 2020 | 382,000.00 |
| Dec 31, 2019 | 382,000.00 |
| Dec 31, 2018 | 380,000.00 |
| Dec 31, 2017 | 380,000.00 |
| Dec 31, 2016 | 263,000.00 |
| Sep 30, 2012 | 2.20 Mn |
| Dec 31, 2011 | 2.49 Mn |
| Sep 30, 2011 | 2.50 Mn |
| Dec 31, 2010 | 2.58 Mn |
| Sep 30, 2010 | 2.60 Mn |
| Dec 31, 2009 | 158,000.00 |
| Sep 30, 2009 | 124,000.00 |